Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 29, 2023 07:30 ET | Source: Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals Announces Management Change

– CEO and Founder Scott Tarriff Retires – – Chairman Michael Graves to Serve as Interim Executive Chairman – WOODCLIFF LAKE, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals,...
November 09, 2023 07:30 ET | Source: Eagle Pharmaceuticals, Inc.

Eagle Delays Third Quarter 2023 Results and Conference Call

WOODCLIFF LAKE, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it will be delaying the release of its third...
November 08, 2023 08:30 ET | Source: Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals to Host Third Quarter 2023 Financial Results on November 9, 2023

WOODCLIFF LAKE, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its third quarter 2023...
October 24, 2023 08:40 ET | Source: Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals Granted Patent for PEMFEXY®

WOODCLIFF LAKE, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Patent and Trademark Office has granted...
October 23, 2023 06:50 ET | Source: Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMS

-- J-code is effective January 1, 2024, and transitional pass-through status became effective October 1, 2023, facilitating patient access -- -- BARHEMSYS is the first and only antiemetic...
October 04, 2023 06:50 ET | Source: Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals Awarded First Prize for Poster to Be Presented at the International Society for Anaesthetic Pharmacology 32nd Annual Meeting

-- Study reports on an interim analysis of the pharmacokinetics and pharmacodynamics of remimazolam and a subsequent model-based optimization of the dosing regimen that is being studied in the trial...
September 19, 2023 16:05 ET | Source: Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023

WOODCLIFF LAKE, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian...
September 11, 2023 06:50 ET | Source: Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals to Present CAL02 Trial in Progress at the 2023 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

-- CAL02 is a unique therapeutic agent that is designed to work differently from antibiotics, aiming to disarm an infectious pathogen’s virulence factors to reduce damage and mitigate disease ---- The...
August 30, 2023 06:50 ET | Source: Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals to Present BYFAVO® (remimazolam) for Injection Abstract at Prestigious Society for Neuroscience in Anesthesiology and Critical Care (SNACC) Conference

WOODCLIFF LAKE, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has been selected to present a platform...
August 29, 2023 06:50 ET | Source: Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women

Eagle plans to file a new drug application (“NDA”) for EA-114 in 2024 EA-114 is anticipated to meaningfully optimize the dosing regimen for all fulvestrant patients and provide the opportunity for...